参考文献:[1]Cernea S, Raz I. Therapy in the early stage: increyins [J]. Diabetes Care, 2011,34(Suppl 2): S264-S271.[2]Schwartz SS, Epstein S,Corkey BE, et al. The time is right for a new classification system for diabetes: rationale and implications of the β-cell-centric classification schema [J ]. Diabetes Care,2016,39(2):179-186.[3]American Diabetes Association. Standards of Medical Care in Diabetes-2022[J]. Diabetes Care, 2022,45(Suppl) : S1- S258.[4]中华医学会糖尿病学分会。中国2型糖尿病防治指南(2020年版)[J]. 国际内分泌代谢杂志,2021,41 (5): 482-548.[5] 《德谷胰岛素利拉鲁肽注射液临床应用专家指导建议》[J]. 中华糖尿病杂志, 2023, 15(3):209-215[6]Kumar A. Insulin Degludec/liraglutide: innovation-driven combination for advancement in diabetes therapy [J]. Expert Opin Biol Ther,2014,14(6): 869-878.[7]母义明,胡蓓。新型糖尿病治疗药物:德谷胰岛素利拉鲁肽注射液[J].临床药物治疗学杂志,2022; 20(6): 16-20. “此文仅用于向医疗卫生专业人士提供科学信息,不代表平台立场”